Bridging the Gap: Communication between Healthcare Companies and Providers vs Data Analysis

Doctor being interviewed

In the dynamic landscape of the healthcare industry, the abundance of market data is a valuable asset for companies seeking to make informed decisions regarding product strategies and planning. However, the importance of direct communication with doctors, healthcare providers, and stakeholders cannot be overstated. Let’s see why fostering open lines of communication between healthcare companies and those on the frontline of patient care is essential for navigating the complexities of the industry and making impactful decisions in a particular market.

  1. Understanding Real-World Challenges

While market data provides a comprehensive overview of trends, challenges, and potential opportunities, it may not capture the nuanced, day-to-day realities faced by healthcare providers. Market data is undoubtedly a valuable tool for healthcare companies, providing a macro-level view of the industry. Direct communication with doctors and healthcare professionals serves as a vital bridge between statistical insights and the lived experiences of those delivering care. Direct conversations allow companies to gain insights into the practical challenges encountered in patient care, enabling them to tailor their products and services to meet the genuine needs of the healthcare community. Interviews and focus groups with healthcare providers also help to understand better market data and foresee the future trends more accurately.

While market data might highlight broad issues such as rising healthcare costs or increasing demand for certain services, direct interactions with doctors and other stakeholders offer a detailed understanding of the specific hurdles faced in diagnosis, treatment, and patient management. These insights help healthcare companies tailor their strategies to address the genuine needs of healthcare professionals and, by extension, the patients they serve.

Doctors and healthcare providers face numerous challenges in their day-to-day work, ranging from administrative burdens to the need for improved communication tools. By engaging in discussions with these professionals, healthcare companies can identify and address the pain points that may not be evident from market data alone. This proactive approach allows companies to develop solutions that alleviate the burdens on healthcare providers, contributing to improved job satisfaction and, in turn, better patient care.

Market data can sometimes be complex and challenging to interpret accurately. Direct interactions with healthcare providers serve as a valuable resource for healthcare companies to enhance their understanding of market trends. Doctors can provide context, share insights into the factors influencing data trends, and offer perspectives on how certain developments might impact their clinical practices. This collaborative exchange of information enables companies to interpret market data more effectively and make decisions grounded in a nuanced understanding of the healthcare landscape.

Interviews and ongoing conversations with healthcare providers go beyond addressing immediate challenges; they also serve as a crucial tool for anticipating future trends. Healthcare professionals, with their frontline experience, are often adept at foreseeing shifts in patient demographics, emerging healthcare technologies, and evolving treatment paradigms. By actively engaging with doctors, healthcare companies position themselves to adapt to these changes proactively, staying ahead of the curve and aligning their strategies with the evolving needs of the healthcare community.

  1. Customizing Solutions for Diverse Needs

Healthcare is not a one-size-fits-all industry. Different medical specialties, regions, and healthcare settings have unique requirements that may be hidden in market data and trends. Engaging in conversations with doctors and providers through direct interviews and focus groups allows healthcare companies to understand the diverse needs of various segments of the industry. This understanding is crucial for tailoring products, services, and innovations to meet the specific demands of different healthcare contexts.

  1. Improving Product Development and Innovation

Direct communication with healthcare providers is a catalyst for innovation. Doctors and frontline staff witness firsthand the gaps in existing healthcare solutions, often before market trends are disclosed in market data, and can provide valuable input on how products can be improved, or new solutions developed. This collaborative approach ensures that healthcare companies are not just meeting market demands but are actively contributing to advancements in patient care through innovation and responsive product development.

  1. Ensuring Regulatory Compliance

The healthcare industry is heavily regulated, and compliance with evolving standards is paramount. Regular dialogue with healthcare providers and stakeholders helps companies stay abreast of changes in regulations and compliance requirements. This proactive approach not only mitigates risks but also fosters a collaborative relationship with healthcare professionals who appreciate companies that prioritize adherence to ethical and legal standards.

Doctors focus groups

  1. Building Trust and Credibility

Trust is a cornerstone of successful healthcare partnerships. Engaging in open and transparent communication with doctors and healthcare providers builds trust and credibility for healthcare companies. Establishing trust is especially important in an industry where the consequences of decisions can directly impact patient outcomes. Trustworthy relationships foster a collaborative environment, paving the way for mutually beneficial partnerships. This is difficult to achieve crunching and analyzing data.

  1. Addressing Healthcare Disparities

Healthcare disparities persist globally, and a deep understanding of these issues is essential for creating equitable solutions. Direct conversations with healthcare providers, particularly those serving diverse populations, offer invaluable insights into the root causes of disparities. By actively engaging with stakeholders, healthcare companies can work towards developing strategies that address these disparities and contribute to improving healthcare access and outcomes for all.

In a nutshell:

In the biotech and healthcare industry, where decisions can have profound effects on companies and patient care, market data alone is insufficient for making well-informed choices. Direct communication with distributors, other company service providers, doctors, healthcare providers, and other stakeholders as a general rule, bridges the gap between data-driven insights and the real-world challenges faced by healthcare companies and those delivering care. By actively engaging with frontline professionals, healthcare companies can tailor their strategies, products, and services to meet the ever-evolving needs of the industry, fostering innovation, trust, and ultimately contributing to the improvement of healthcare on particular markets and at a global scale.

Discover our services.

Gene therapy could cure some migraine subtypes

What is gene therapy?

Gene therapy is a disruptive technology that could change the paradigm to treat a disease if it is proven effective.

Up to now, when scientists discovered a new gene potentially involved in the advent of a disease subsequent research mainly evolved around potential development of new products that targeted this new gene as well as associated interacting proteins and biochemical pathways. Nonetheless the future may bring along new approaches as science and technology advance.

Gene therapy in the treatment of migraine

Gene therapy is a technique to transfer genetic material targeting specific cells to repair, replace or inactivate malfunctioning genes that produce either defective proteins or no proteins at all in order to prevent or treat a disease. To transfer a gene, it is necessary to make use of a vector that is generally a genetically engineered virus prepared to cause no harm to the patient. The vector is injected or given intravenously, though in variant techniques a sample from the patient’s tissue can be extracted and exposed to the vector to be returned to the patient afterwards. The viruses infect targeted cells transferring the modified genetic material that will ultimately cause the desired therapeutic effect.

However not everything is as easy as it looks. Gene therapy conveys high health risks and at the moment it is only considered for those diseases that have no cure and whose genes are properly identified. The main barrier to manipulate genes is based on the fact that genes may control many biochemical pathways directly and indirectly, what is known as pleiotropic proteins. These genes often influence in the advent of other potential diseases and / or side effects in the same individual at the same time.

Since 1999 some attempts to use gene therapy have been tried with partial success. In one study conducted by a team of French researchers, eleven children suffering from serious immunodeficiency were treated with limited success, but two of them developed leukemia due to the vector used to transfer the genetic material. Other cases together with opinionated experts have also questioned gene therapy viability.

More recently CRISPR technology, an innovative genetic editing system, has raised great expectations once more. Nevertheless, according to Stanford University, patients receiving this treatment often develop antibodies against Cas9, an enzyme used in this new technology that cuts DNA fragments precisely. According to experts in this field, it is possible, however, to find workarounds such as different nucleases that do not prompt the autoimmune reaction so strongly and / or administration of immunosuppressants.

CRLifeSc recommends this book as part of its affiliate marketing program. This volume presents a list of cutting-edge protocols for the study of CRISPR-Cas defense systems and their applications at the genomic, genetic, biochemical and structural levels.

Yet, the autoimmune system is not the only problem to be overcome when dealing with gene therapy and this technique. Further studies seem to show that there is also a risk of developing tumors due to a defective P53 gene. This gene codes for a protein that protects DNA from damaging changes, thus preventing potential tumors and other unwelcome effects. So, when P53 gene does not work properly DNA modification and desired therapeutic effect are easier, but they are also riskier. Some researchers believe that cell culture in a lab could be a solution to this problem, testing those genetically modified cells that have kept a functional P53 gene in a sort of quality control before reimplantation. In conclusion the use of this technique is still far from being implemented soon, and experts believe that it will probably be carried out in a very different way. Targeting RNA instead of DNA could also be another way to overcome DNA-related technical problems.

Migraine genetics

Gene therapy products are considered “biological products”. In the United States, this type of product is regulated by the FDA’s Center for Biologics Evaluation and Research (CBER). Clinical studies in humans require the submission of an investigational new drug application (IND) before clinical trials are conducted in the United States. Marketing a gene therapy product requires submission and approval of a “biologics license application” (BLA).

European Union regulations define “biological medicinal products” as “a protein or nucleic acid–based pharmaceutical substance used for therapeutic or in vivo diagnostic purposes, which is produced by means other than direct extraction from a native (nonengineered) biological source“. The terms “biotechnology medicines” and “biological medicinal products” are also commonly used.

 A quick look at migraine genetics

It is generally accepted that migraine is a multifactorial disorder with multiple genes playing a low penetrance role that is also influenced by environmental non-genetic factors. Thus, migraine is categorized in different subtypes, though it is mainly classified as a neurovascular condition activated from the trigeminovascular system where neurotransmitter pathways apparently play a relevant part, on their turn also controlled by other genes.

Genes that take part in migraine are often categorized as neurotransmitter genes, vascular genes and hormone genes. To get an idea of the complexity of migraine etiology we can give some examples of genes and proteins that take part in this medical condition, but it is far from being an exhaustive explanation for migraine origin, which is still unknown. There is some evidence that trigeminal nociceptive terminals are activated prompting the release of CGRP (calcitonin gene-related peptide), a pleiotropic neurological intermediary. CGRP is a 37 aminoacid peptide which seems to increase the sensitivity of perivascular nociceptors and dilate cranial vessels for some individuals who seem to be more susceptible, eventually known as migraineurs. RAMP1 gene (receptor activity modifying protein 1) codes for a key receptor subunit of CGRP, therefore also playing a relevant role. Still not all migraines are linked to CGRP and therefore not all patients may benefit from treatments targeting this peptide. Other genes may be the essential cause of a migraine, for example pituitary adenylate cyclase-activating polypeptide (PACAP), which is a neuronal messenger molecule thought to influence migraine, or female sex hormones involved in migraine susceptibility. There are many more genes and biochemical pathways suspected of influencing this medical condition.

At the moment, only some hemiplegic migraine subtypes have been accurately identified with causative genes. CACNA1A on chromosome 19p13 (FHM1), ATP1A2 at 1q23 (FHM2), and SCN1A at 2q24 (FHM3). It seems that FHM1, FHM2 and FHM3 mutations increase levels of glutamate and potassium in the synaptic cleft. PRRT2 (proline rich transmembrane protein 2) mutations have also been associated with hemiplegic migraine.

 Are there any clinical trials being conducted to treat migraine with gene therapy?

There are currently a significant number of studies making use of gene therapy to treat hereditary conditions. Examples include several types of cancer, immunodeficiency, sickle cell disease, diabetes concurrent with hepatocellular carcinoma, hemophilia, Alzheimer Disease and others mainly in early stages of development, though some studies have reached phase III trials as it is the case of peripheral arterial disease or spinal muscular atrophy.

We are not aware of any studies being conducted to treat migraine with gene therapy at the moment.

CRLifeSc, as part of its affiliate marketing plan that helps to maintain this website, recommends the following book  related to essential molecular methods for developing gene transfer systems and methods for introducing genes into specific tissue types either in vivo or ex vivo.

Gene Therapy Protocols

Are there any patents filed related to the treatment of migraine through gene therapy?

Some universities, research institutions and several pharmaceutical companies have filed patent applications related to diagnostic markers or genes involved in migraine such as those concerned with or affecting CGRP among others.

More directly related to gene therapy, there are already thousands of patent applications disclosing vector systems, antibodies, delivery techniques, enhancers, and different methods and techniques targeting specific genes or just genes in general. In particular, there are hundreds of patent applications filed in relation with CRISPR (clustered regularly interspaced short palindromic repeats) technology.

Regarding p53 gene activity concerns, as an example among many others we can mention MultiVir Inc., an American company, that filed international patent publication number WO2009094647 in January 2009 describing p53 biomarker profiles to be used in anti-hyperproliferative disease gene therapy.

In any case we have not found any patents specifically describing treatment of any migraine subtype through gene therapy yet.

 Is it possible to cure migraine with gene therapy?

For the moment advances in migraine genetics may help identify how genes influence biological pathways to develop more targeted drugs for migraine therapy.

Meanwhile the future treatment of migraine seems better approached with personalized medicine or precision medicine improving the definition of disease subtypes and more precise biomarkers that allow better tailor-made treatments for specific patients. Data mining and analysis in genetics, biochemistry and lifestyle will help to develop this type of personalized medicine.

Certainly, there is hope that gene therapy could cure at least some migraine subtypes in the near future, but gene therapy techniques need a significant improvement together with more advances and better understanding of migraine genetics. Maybe the best migraine subtype candidate to be approached through gene therapy is hemiplegic migraine variants – that is certain types of familial hemiplegic migraine and sporadic hemiplegic migraine.

To know more about the antimigraine market please follow this link

Case-Based Diagnosis and Management of Headache Disorders Case-Based Diagnosis and Management of Headache Disorders

This book provides the practicing physician with a practical approach to the diagnosis, evaluation and management of headache disorders based on lessons learned from real-life headache patients. Internationally well-known headache experts present cases from their own practice and discuss the evaluation and management of each case step by step. The clearly structured chapters cover initial evaluation and diagnostic work-up, imaging, differential diagnosis, interpretation of findings of further work-up, treatment options and response and key points. A wide spectrum of headache types is covered, including both primary and secondary headache disorders. The reader will learn how to diagnose and manage different headache disorders directly from the clinical experience of experts. Case-Based Diagnosis and Management of Headache Disorders will be of value for neurologists and a wide range of physicians ? from those in other specialties to primary care givers.


The information provided in this article is not a substitute for professional medical advice, diagnosis, or treatment. You should not rely upon the content provided in this article for specific medical advice. If you have any questions or concerns, please talk to your doctor.

These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.